Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesQ32 Bio Inc

Q32 Bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
9.43 USD 0.18 ( 1.95%)
Last update at 2026-11-09T15:41:00Z
VOLUME
80586
Market Cap
0.00M

Momentum Score

…

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.01
Low
9.58
High
52 Week Price Range
8.24
Low
32.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Q32 Bio Inc (NASDAQ: QTTB) is limited; regulatory filings identify it as a biotechnology company but detailed disclosures about its pipeline, platform and commercial strategy are sparse. Its long-term prospects would depend on successful progression of any development programs, regulatory approvals and strategic partnerships, which may benefit investors seeking early-stage biotech exposure.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.25
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-
Net Debt
-37.95M
ROCE
-31.27%
Diluted EPS TTM
-

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -87.08M -42.75M -37.02M -128.69M -103.92M
Net income -112.96M -42.81M -37.56M -128.69M -103.92M
Selling general administrative - 10.06M 6.76M - -
Gross profit 0.58M 4.05M 24.43M 2.70M 1.67M
Reconciled depreciation - 0.37M 0.05M - -
Ebit -92.10M -36.82M -36.69M -130.26M -109.94M
Ebitda -91.52M -36.45M -36.65M -121.36M -103.62M
Depreciation and amortization 0.58M 0.37M 0.05M 8.90M 6.32M
Operating income -92.10M -39.23M -36.69M -130.26M -109.94M
Other operating expenses 93.26M 45.88M 36.69M 132.97M 111.61M
Tax provision - 0.06M 0.55M - -
Income tax expense 25.88M 0.06M 0.55M -0.00M -
Total revenue 1.16M 6.65M 33.97M 2.70M 1.67M
Total operating expenses 92.68M 45.88M 36.69M 124.06M 105.29M
Cost of revenue 0.58M 2.60M 9.54M - -
Total other income expense net 5.02M -3.52M -0.32M 1.57M 6.03M
Net income from continuing ops - -42.81M -37.56M - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 306.12M 61.77M 35.15M 263.74M 310.57M
Other current assets 1.26M 0.15M 0.07M 1.73M 3.79M
Total liab 233.13M 192.49M 124.36M 67.74M 52.06M
Total stockholder equity 72.99M -130.71M -89.21M 196.00M 258.51M
Other current liab 7.02M 9.03M 1.09M 9.80M 8.96M
Common stock 0.01M 0.00M 0.00M 0.01M 0.00M
Capital stock - 0.00M 0.00M - -
Retained earnings -542.10M -133.34M -90.53M -328.37M -199.67M
Cash 39.27M 43.89M 32.25M 217.43M 53.77M
Total current liabilities 11.57M 57.87M 7.22M 22.66M 12.37M
Current deferred revenue - 14.53M 3.21M 5.63M 0.81M
Net debt -37.95M 0.84M -27.27M -201.99M -53.77M
Short term debt 1.32M 32.87M 0.25M 2.50M -
Short long term debt - 32.40M - - -
Short long term debt total 1.32M 44.73M 4.97M 15.44M -
Other stockholder equity 615.09M 2.62M 1.32M 524.36M 457.99M
Total current assets 83.91M 46.85M 34.00M 219.56M 266.58M
Short term investments 43.39M 141.04M 47.49M - 208.61M
Net receivables - 1.06M 0.91M 0.40M 0.40M
Long term debt - 5.07M 4.97M - -
Inventory - 1.75M 0.77M - 0.00M
Accounts payable 3.23M 1.44M 2.68M 4.72M 2.61M
Accumulated other comprehensive income -0.01M -0.40M -0.01M - 0.18M
Non currrent assets other - -20.06M -1.00M - -
Non current assets total 222.21M 14.92M 1.15M 44.17M 43.99M
Capital lease obligations - 7.26M 0.00M - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments - -2.47M -0.16M - -
Total cash from financing activities 0.18M 30.07M 20.11M 53.09M 158.21M
Net income -112.96M -42.81M -37.56M -128.69M -103.92M
Change in cash 5.28M 16.65M -12.94M 163.66M 15.55M
Begin period cash flow 33.99M 32.89M 45.92M 53.77M 38.22M
End period cash flow 39.27M 49.54M 32.98M 217.43M 53.77M
Total cash from operating activities -96.23M -10.96M -32.98M -94.33M -91.36M
Issuance of capital stock - 0.07M 20.11M - -
Depreciation 0.58M 0.37M 0.05M 8.90M 6.32M
Other cashflows from financing activities 101.33M -2.47M -0.16M 204.90M -51.80M
Capital expenditures 0.23M 2.48M 0.16M 3.73M 21.83M
Change in working capital -7.21M 26.94M 3.68M 11.52M 0.46M
Stock based compensation - 1.24M 0.75M - -
Other non cash items 22.43M 0.88M 0.10M 29.29M 22.86M
Free cash flow -96.46M -13.44M -33.14M -98.06M -113.19M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
QTTB
Q32 Bio Inc		 0.18
1.95%		 9.43 - - - -
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Q32 Bio Inc

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

830 Winter Street, Waltham, MA, United States, 02451

781 999 0232

https://www.q32bio.com

39

Name Title Year Born
Ms. Jodie Pope Morrison CEO, Secretary & Director 1975
Dr. David S. Grayzel M.D. President & Director 1969
Dr. Shelia M. Violette Ph.D. Co-founder, Chief Scientific Officer & President of Research NA
Mr. Lee H. Kalowski M.B.A. Chief Financial Officer 1981
Dr. Saul Fink Ph.D. Chief Technology Officer NA
Mr. David Appugliese J.D. Senior VP & Head of People NA
Ms. Maria Marzilli M.P.H. Executive Vice President of Corporate Strategy & Program Operations NA
Ms. Kathryn E. Golden M.B.A. Head of Chemistry, Manufacturing & Controls NA
Dr. Jason A. Campagna M.D., Ph.D. Chief Medical Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…